Streptococcus pneumoniae is a major cause of morbidity and mortality, globally causing more deaths than any other infectious disease. At highest risk are the smallest children and elderly, with approximately one million children below 5 years of age dying, annually (CDC). Pneumococcal diseases range from mild respiratory tract mucosal infections, such as sinusitis, to more severe diseases such as pneumonia, septicaemia and meningitis.
The Native Antigen Company are committed to supporting research into Streptococcus, offering specific monoclonal antibodies to this bacterium.
Streptococcus pneumoniae is a lancet-shaped, gram-positive, facultative anaerobic bacterium. In humans, S. pneumoniae primarily colonizes the nasopharynx and transmission occurs from person-to-person via respiratory secretions from patients infected wit, S. pneumoniae, and from healthy carriers. In susceptible individuals, the bacteria can spread to the lower respiratory tract, the inner ear or sinuses, to cause a range of illnesses, referred to as pneumococcal disease.
Worldwide, S. pneumoniae is the major cause of pneumonia, sepsis, and meningitis and the leading cause of community-acquired pneumonia in young children and the elderly.
Streptococcus pneumoniae Antigens
The Native Antigen Company are pleased to offer a Streptococcus pneumoniae native lysate for use in the development of immunoassays.
Streptococcus pneumoniae Antibodies
The Native Antigen Company are pleased to offer a pair of monoclonal antibodies that are specific to Streptococcus pneumoniae, which are suitable for use in the development of immunoassays.
Check out our FAQ section for answers to the most frequently asked questions about our website and company.